Intranasal administration
US11730904B2 · kind B2 · utility
0Cited by
63References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 4, 2021 |
| Grant date | Aug 22, 2023 |
| Priority date | — |
| Expiry date | Feb 2, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61M2210/0618
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A delivery device for and method of modulating a condition relating to social cognition and/or behaviour in a human subject using oxytocin, non-peptide agonists thereof and/or antagonists thereof, comprising: providing a nosepiece to a first nasal cavity of the subject; and providing a supply unit for administering less than 24 IU of oxytocin, non-peptide agonists thereof and/or antagonists thereof through the nosepiece to an upper region posterior of the nasal valve which is innervated by the trigeminal nerve.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.